Covered recipient · General Payments record
ALYSSA SORIANO
General Payments · PY2025
$667.05
- Reported across 15 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2025 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $634.78 | 14 |
| Education | $32.27 | 1 |
By paying entity
PY2025 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $399.56 | 8 |
| ITI, Inc. | $143.06 | 2 |
| Indivior Inc. | $55.89 | 2 |
| Teva Pharmaceuticals USA, Inc. | $26.29 | 1 |
| Lilly USA, LLC | $22.05 | 1 |
| Amgen Inc. | $20.20 | 1 |
By program year
All program years on this page · sorted by year
| Program year | Amount | Records |
|---|---|---|
| PY2025 | $667.05 | 15 |
Payment records · PY2025 (15)
Ordering applied by this site (paying entity, then date) · record values are shown as CMS published them
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $20.20 | 11/07/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1229088150 | CMS |
| Indivior Inc. | $28.40 | 09/17/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1240563317 | CMS |
| Indivior Inc. | $27.49 | 11/06/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1240563323 | CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $121.68 | 10/29/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1241679955 | CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $21.38 | 12/09/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1241679959 | CMS |
| Lilly USA, LLC | $22.05 | 06/12/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1187059001 | CMS |
| Novo Nordisk Inc | $13.78 | 07/22/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188730873 | CMS |
| Novo Nordisk Inc | $9.05 | 08/12/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1189039406 | CMS |
| Novo Nordisk Inc | $86.19 | 08/19/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188528084 | CMS |
| Novo Nordisk Inc | $15.97 | 09/04/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188867621 | CMS |
| Novo Nordisk Inc | $32.27 | 09/05/2025 | Education | Undisputed | 06/30/2026 | 1188663737 | CMS |
| Novo Nordisk Inc | $2.30 | 09/24/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188864171 | CMS |
| Novo Nordisk Inc | $115.00 | 10/22/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188454182 | CMS |
| Novo Nordisk Inc | $125.00 | 12/04/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188719598 | CMS |
| Teva Pharmaceuticals USA, Inc. | $26.29 | 12/15/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1247469490 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2025
- Source files
- Dataset page · Bulk file · PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.